Enanta Pharmaceuticals | ENTA - Betriebsaufwand





Betriebsaufwand Veränderung Datum
AbbVie USD 10.27B 538M 2026-03
Amgen USD 4.78B 1.12B 2026-03
Anika Therapeutics USD 133.9M 103.93M 2026-03
Arrowhead Research USD 223.22M 10.86M 2025-12
AstraZeneca USD 8.18B 4.35B 2026-03
BioCryst Pharmaceuticals USD 146.17M 534.06M 2025-12
Biogen USD 1.96B 69.6M 2026-03
Bristol-Myers Squibb USD 20.07B 11.77B 2026-03
Enanta Pharmaceuticals USD 126.59M 346.51M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
GlaxoSmithKline GBP 5.34B 1.85B 2026-03
Halozyme Therapeutics USD 211.07M 74.73M 2025-12
Heron Therapeutics USD 40.55M 1.46M 2025-12
Immunic USD 23.33M 2.67M 2025-12
Incyte USD 5.62B 4.5B 2026-03
Insmed USD 513.55M 109.86M 2025-12
Ionis Pharmaceuticals USD 364M 54M 2026-03
J&J USD 17.44B 1.53B 2026-03
Karyopharm Therapeutics USD 51.92M 9.9M 2025-12
Ligand Pharmaceuticals USD 8.29M 32.17M 2025-09
Merck USD 18.17B 8.01B 2026-03
Neurocrine Biosciences USD 577.6M 22M 2025-12
Novartis USD 9.29B 507M 2026-03
Novavax USD 126.2M 23.62M 2025-12
Pfizer USD 90.1B 77.19B 2026-03
PTC Therapeutics USD 246.3M 38.78M 2025-12
Roche Holding CHF 21.01B 10.84B 2025-12
Sarepta Therapeutics USD 853.02M 390.78M 2025-12
Vertex Pharmaceuticals USD 1.85B 78.6M 2026-03